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Introduction
Picrorhiza kurroa Royle ex. Benth belongs to Scrophu-
laraceae family and is commonly called Kutki or Kutka. 
It is a well-recognized herb in the Ayurvedic and Chinese 
traditional medicine. It is a wonder herb with hepatopro-
tective (1-4), anticholestatic (5), antioxidant (6), antidia-
betic (7) and immune-modulating properties (8-10). The 
leaves, root and rhizome of Picrorhiza are effective in nu-
merous ailments namely liver and upper respiratory tract 
illnesses, chronic diarrhea, malaria, jaundice, epilepsy, 
paralysis, rheumatoid arthritis and skin diseases (11-14). 
In rats with malaria, Picrorhiza reestablished depleted 
glutathione levels helping to conserve a normal oxidation-
reduction balance (15).
Additionally, Picrorhiza extract has been found to be use-
ful in dealing with viral hepatitis symptoms as it has favor-
able anti-hepatitis B surface antigen potential (16). 
Nowadays plants or plant extracts have important thera-
peutic applications in both Western and Eastern medici-
nal systems. However, some of them are potentially toxic, 
mutagenic or carcinogenic. Thus, to evaluate potential 
genotoxicity of the standardized hydro-alcoholic extract 
of Picrorhiza kurroa rhizome, mammalian chromosomal 
aberration test was conducted on cultured human periph-
eral blood lymphocytes.
Material and Methods
Material
Picrorhiza kurroa rhizomes were procured from Patanjali 
Natural Coloroma Pvt Ltd and stored in ambient condi-
tions for further study. The other solvents and chemicals 
were purchased from Sigma-Aldrich, India.
Extraction
The rhizomes of the plant were dried in shade for about 3 
weeks and ground using a mixer to a coarse powder. Using 
a soxhlet extraction method, the powder of dried rhizome 
was processed with petroleum ether (40-50oC) for 18 h in 
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order to remove fat and unwanted components. The treat-
ed powder was further processed with hydro-alcoholic 
solution (60:40) by using the same extraction procedure 
for 18h. The extract was evaporated to dryness in a ro-
tary flash evaporator at a temperature not exceeding 60°C, 
then stored in an air tight container.
Test system
Human venous blood from healthy adult donors lacking 
current viral infections was collected and used for the 
study. The study was conducted in accordance to the pro-
cedures and recommendations of OECD Guideline 473, 
updated and adopted July 1997.
The study was conducted in two independent phases: 
Initial Chromosome Aberration Assay (Phase I)
Confirmatory Chromosome Aberration Assay (Phase II) 
Based on the results of solubility, it was tested up to the 
highest concentration 2500 µg/mL (both phases of the 
experiment). Dose range finding study was conducted as 
an integral part of the chromosomal aberration assay. A 
range of soluble dose concentrations ranging viz., 2500, 
1250, 625, 312.5, 156.3, 78.1, 39.1, 19.5, 9.8 and 4.9 µg/mL 
was applied in the initial chromosome aberration assay.
In the first phase of the experiment, the proliferating 
human lymphocytes (72 ± 2 hours after the initiation of 
whole blood culture) were exposed at various doses of the 
Test Sample (4.9, 9.8, 19.5, 39.1, 78.1, 156.3, 312.5, 625, 
1250 and 2500 µg/mL) in the absence and presence of 
metabolic activation system (1% v/v) for a short duration 
(about 4-hour exposure).
In the second phase of the experiment, the proliferating 
human lymphocytes (72 ± 2 hours after the initiation of 
whole blood culture) were exposed at diverse dose levels 
of the Test Sample (2500, 1500, 1000, 750 and 500 µg/mL) 
in the absence of metabolic activation system for a contin-
uous treatment (up to 1.5 normal cell cycle length). One 
set of the proliferating human lymphocytes were exposed 
at various dose levels of Test Sample (2500, 1500, 1000, 
750 and 500 µg/mL) in presence of metabolic activation 
system (1% v/v) for a short duration (about 4-hour expo-
sure). 
In both the phases (Experimental Phase 1 & 2) the treated 
cells were harvested at about 1.5 cell cycle length after 
treatment (22 hours). Mitomycin C and Cyclophospha-
mide were used as positive control substances for experi-
ments without and with S9, respectively.
During harvesting of cell cultures, the cells were treated 
with metaphase arresting agent (Colchicine) 2 hours prior 
to harvesting. Later the cells were hypotonically treated, 
fixed in acetomethonol fixative and metaphase spreads 
were prepared by hanging drop method. The slides were 
stained with 5% Giemsa solution.
The metaphase cells were analyzed microscopically for the 
presence of chromosome aberrations if any, and a mini-
mum number of 1000 cells per sample were screened ran-
domly and number of metaphases was recorded in differ-
ent fields to determine the mitotic index. The number of 
aberrant cells with one or more aberrations excluding gaps 
and the number of aberrant cells with one or more aberra-
tions including gaps was recorded separately to calculate 
percent aberrant cells.
Results
Initial chromosome aberration assay
The initial chromosomal aberration was conducted with 
about 4-hour exposures to standardized Picrorhiza kur-
roa rhizome extract (Test Sample), in the presence and 
absence of S9 metabolic activation system. The assay was 
carried out with ten dose levels of the Test Sample viz., 
2500, 1250, 625, 312.5, 156.3, 78.1, 39.1, 19.5, 9.8 and 4.9 
µg/mL in the final culture. The result of mitotic indices at 
all the ten concentrations of the Test Sample was found to 
be comparable to the vehicle control group. The results of 
chromosome aberrations including gap and chromosome 
aberration excluding gap at various dose concentrations 
(2500, 1250, 625 µg/mL) did not reveal any induction of 
chromosome aberrations when compared to the vehicle 
control groups (Tables 1 and  2).
The results of the positive control, Mitomycin C (2.0 µg/
mL; in the absence of metabolic activation) and Cyclo-
phosphamide (60 µg/mL; in the presence of metabolic 
activation 1% v/v) significantly increased the number of 
structural chromosome aberrations when compared to 
vehicle control groups. 
Therefore, it is clear from the results of the initial chro-
mosomal aberration assay that Picrorhiza kurroa rhizome 
extract, in the presence and absence of S9 metabolic acti-
vation system does not induce chromosome aberrations 
at concentrations tested. However, the positive control 
groups showed an increase in the frequency of aberrant 
cells and thus demonstrated sensitivity of the test system.
Confirmatory chromosome aberration assay 
The confirmatory assay was performed after the results of 
the initial trial were known. The clear negative result of 
the initial chromosome aberration assay was further con-
firmed for the evidence of clastogenicity, if any.
Assay without S9 activation-continuous exposure
Three days after culture initiation, the cultures were treat-
ed with the Test Sample, in the absence of metabolic acti-
vation at various dose concentrations (2500, 1500, 1000, 
750 and 500 µg/mL) along with concurrent vehicle and 
positive controls. Incubation at 37± 2oC was continued 
until the time of harvest. The results of mitotic indices at 
all the five concentrations of the Test Sample were found 
to be comparable to the vehicle control group. No cyto-
toxicity was observed at any of the dose levels of the Test 
Sample, in the absence of metabolic activation. The results 
of chromosome aberrations including gap and chromo-
some aberration excluding gap at various concentrations 
(2500, 1500, 1000 µg/mL) did not reveal any induction of 
chromosome aberrations when compared to the vehicle 
control groups. 
The results of the positive control, Mitomycin C (2.0 
µg/mL) in the absence of metabolic activation showed a 
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considerable increase in the number of structural chro-
mosome aberrations when compared to vehicle control 
groups (Tables 3-5).
Therefore, confirmatory chromosome aberration assay 
clearly indicate that the Test Sample, in the absence of 
S9 metabolic activation system does not induce chromo-
some aberrations at the concentrations tested. However, 
the positive control group showed an increase in the fre-
quency of aberrant cells and thus demonstrated sensitivity 
of the test system.
Assay with S9 activation–short exposure 
The confirmatory chromosome aberration assay was con-
ducted with about 4-hour exposures to the Test Sample, in 
the presence of activation system. The assay was carried 
out at five concentrations of the Test Sample (2500, 1500, 
1000, 750 and 500 µg/mL). 
The results of mitotic indices at all the five concentrations 
of the Test Sample, were found to be comparable to the ve-
hicle control group. No cytotoxicity was observed at any of 
the dose levels of the Test Sample in the presence of meta-
bolic activation. The results of chromosome aberrations 
including gap and chromosome aberration excluding gap 
at various dose concentrations (2500, 1500, 1000 µg/mL) 
in the presence of metabolic activation did not reveal any 
induction of chromosome aberrations when compared to 
Table 1. Mitotic Index observed in experimental phase 1 both in absence and presence of metabolic activation (10% v/v)
In presence of metabolic activation (10% v/v) In absence of metabolic activation
Dose levels (µg/mL) Mitotic indexa % Mitotic Index Dose levels (µg/mL) Mitotic index % Mitotic index
0.0 (VC) 13.052 ± 1.01 NA 0.0 (VC) 14.706 ± 0.73 NA
60 (CPA) 10.325 ± 0.73 79 2 (MMC) 8.345 ± 0.30 57
2500 (TS) 12.864 ± 0.43 99 2500 (TS) 13.339 ± 1.22 91
1250 (TS) 11.596 ± 0.45 89 1250 (TS) 14.782 ± 1.30 101
625 (TS) 11.97 ± 0.77 92 625 (TS) 14.222 ± 0.07 97
312.5 (TS) 11.511 ± 0.15 88 312.5 (TS) 14.179 ± 0.81 96
153.25 (TS) 11.692 ± 0.06 90 153.25 (TS) 13.951 ± 0.12 95
78.13 (TS) 11.785 ± 0.01 90 78.13 (TS) 13.493 ± 0.13 92
39.06 (TS) 12.448 ± 0.64 95 39.06 (TS) 14.025 ± 0.67 95
19.53 (TS) 11.420 ± 0.75 87 19.53 (TS) 13.458 ± 0.00 92
9.77 (TS) 12.345 ± 0.34 95 9.77 (TS) 13.290 ± 0.15 90
4.88 (TS) 11.882 ± 0.22 91 4.88 (TS) 14.180 ± 0.03 107
Abbreviations: CPA, Cyclophosphamide (Positive control); MMC, Mitomycin C (Positive control), TS, Test Sample, VC, vehicle control (Dimethyl 
sulfoxide)
a Mitotic index = Number of metaphase cells/total number of cells screened × 100. 
Table 2. Mitotic index observed in experimental phase II with exposure 
of whole blood culture to short term treatment (4 ± 1 hour) in presence 
of metabolic activation system (10% v/v)
Dose Levels (µg/mL) Mitotic index % Mitotic index
0.0 (VC) 13.052 ± 1.01 NA
60 (CPA) 10.325 ± 0.73 79
2500 (TS) 12.864 ± 0.43 99
1500 (TS) 11.596 ± 0.45 89
1000 (TS) 11.97 ± 0.77 92
750 (TS) 11.511 ± 0.15 88
500 (TS) 11.692 ± 0.06 90
Abbreviations: CPA, Cyclophosphamide (Positive control); TS, Test 
Sample, VC, vehicle control (Dimethyl sulfoxide).
Table 3. Mitotic index observed in experimental phase II with exposure 
of whole blood culture to continuous treatment (22 hours) in absence 
of metabolic activation system.
Dose Levels (µg/mL) Mitotic indexa % Mitotic index
0.0 (VC) 13.052 ± 1.01 NA
2  (MMC) 10.325 ± 0.73 79
2500 (TS) 12.864 ± 0.43 99
1500 (TS) 11.596 ± 0.45 89
1000 (TS) 11.97 ± 0.77 92
750 (TS) 11.511 ± 0.15 88
500 (TS) 11.692 ± 0.06 90
Abbreviations:  MMC, Mitomycin C (Positive control), TS, Test Sample, 
VC, vehicle control (Dimethyl sulfoxide).
a Mitotic index = Number of metaphase cells/total number of cells 
screened × 100. 
Table 4. Chromosome aberration analysis in experimental phase I 
with exposure of whole blood culture to short term treatment (4 ± 1 
hour) in absence of metabolic activation system
Dose Levels 
(µg/mL)
% Aberrated cells (structural) % Numerical 
aberrationIncluding Gap Excluding gap
0.0 (VC) 2.00 ± 0.71 0.50 ± 0.71 0.20 ± 0.71
2  (MMC) 12.00 ± 0.41 12.00 ± 0.41 0.00 ± 0.00
2500 (TS) 1.50 ± 0.71 0.50 ± 0.71 0.00 ± 0.00
1250 (TS) 0.50 ± 0.41 0.50 ± 0.71 0.00 ± 0.00
625 (TS) 0.50 ± 0.71 0.00 ± 0.00 0.00 ± 0.00
Abbreviations:  MMC, Mitomycin C (Positive control), TS, Test Sample, 
VC, vehicle control (Dimethyl sulfoxide).
Table 5. Chromosome aberration analysis in experimental phase 
II with exposure of whole blood culture to continuous treatment (22 
hours) in absence of metabolic activation system
Dose Levels 
(µg/mL)
% Aberrated cells (structural) % Numerical 
aberrationIncluding Gap Excluding gap
0.0 (VC) 1.50 ± 0.71 1.50 ± 0.71 0.00 ± 0.00
2  (MMC) 13.00 ± 1.41 12.00 ± 0.00 0.00 ± 0.00
2500 (TS) 1.00 ± 0.00 0.50 ± 0.71 0.00 ± 0.00
1250 (TS) 0.50 ± 0.71 0.50 ± 0.71 0.00 ± 0.00
625 (TS) 0.50 ± 0.71 0.50 ± 0.71 0.00 ± 0.00
Abbreviations:  MMC, Mitomycin C (Positive control), TS, Test Sample, 
VC, vehicle control (Dimethyl sulfoxide).
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the vehicle control groups. 
In the presence of metabolic activation (1%v/v), the posi-
tive control (60 µg/mL Cyclophosphamide) showed a sig-
nificant increase in the number of structural chromosome 
aberrations when compared to vehicle control groups 
(Tables 1, 2, 6, and 7).
Therefore, it is clear from the results of the confirma-
tory chromosome aberration assay that Test Sample, in 
the presence of S9 metabolic activation system does not 
induce chromosome aberrations at the concentrations 
tested. However, the positive control group (Cyclophos-
phamide) showed an increase in frequency of aberrant 
cells and thus demonstrated sensitivity of the test system 
(Figures 1-8).
Discussion
For chromosomal aberration studies, mammalian cells 
were cultured in vitro, exposed to a test substance, har-
vested, and the occurrence of chromosome aberrations 
was measured. Human peripheral blood lymphocytes do 
not normally divide but they are stimulated to divide in 
culture by exposure to Phytohemagglutinin (PHA) (17). 
At predetermined intervals after exposure to the Test 
Sample, the lymphocytes were treated with metaphase ar-
resting substance, Colcemid. Later the cells were collected, 
stained, and investigated for the presence of chromosomal 
aberrations.
Several mutagenic agents did not directly interact with the 
DNA but did so after being converted to active intermedi-
ates by liver enzymes (18). Due to limited capacity of hu-
man lymphocytes to metabolize the test sample an exter-
nal metabolic activation system (rat liver S9 homogenate) 
Table 6. Chromosome aberration analysis in experimental phase 
I with exposure of whole blood culture to short term treatment (4±1 
hour) in presence of metabolic activation system (10% v/v)
Dose Levels 
(µg/mL)
% Aberrated cells (structural) % Numerical 
aberrationIncluding Gap Excluding gap
0.0 (VC) 1.50 ± 0.71 0.50 ± 0.71 0.20 ± 0.71
2  (MMC) 12.5 ± 0.71 12.00 ± 1.41 0.00 ± 0.00
2500 (TS) 1.50 ± 0.71 0.50 ± 0.71 0.00 ± 0.00
1250 (TS) 1.00 ± 0.00 0.50 ± 0.71 0.00 ± 0.00
625 (TS) 0.50 ± 0.71 0.50 ± 0.71 0.00 ±0.00
Abbreviations:  MMC, Mitomycin C (Positive control), TS, Test Sample, 
VC, vehicle control (Dimethyl sulfoxide).
Table 7. Chromosome aberration analysis in experimental phase II 
with exposure of whole blood culture to short term treatment (4±1 
hour) in presence of metabolic activation system
Dose Levels 
(µg/mL)
% Aberrated cells (structural) % Numerical 
aberrationIncluding Gap Excluding gap
0.0 (VC) 1.00 ± 0.41 0.50 ± 0.71 0.20 ± 0.71
2  (MMC) 11.50 ± 0.71 9.50 ± 0.71 0.00 ± 0.00
2500 (TS) 1.50 ± 0.71 0.50 ± 0.71 0.00 ± 0.00
1250 (TS) 0.50 ± 0.71 0.00 ± 0.00 0.00 ± 0.00
625 (TS) 1.00 ± 0.00 0.50 ± 0.71 0.00 ± 0.00
Abbreviations:  MMC, Mitomycin C (Positive control), TS, Test Sample, 
VC, vehicle control (Dimethyl sulfoxide).
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Figure 1. Experimental phase 1 percent aberrant cells observed 
with metabolic activation (including gap) at various concentrations 
of Test Sample.
Figure 2. Experimental phase 1 percent aberrant cells observed 
with metabolic activation (excluding gap) at various concentra-
tions of Test Sample.
Figure 3. Experimental phase 1 percent aberrant cells observed 
without metabolic activation (including gap) at various concentra-
tions of Test Sample
Figure 4. Experimental phase 1 percent aberrant cells observed 
without metabolic activation (excluding gap) at various concentra-
tions of Test Sample
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was incorporated to further improve the conversion as 
well as the ability of the assay to identify the clastogenic 
metabolic intermediates (19,20).
Numerical aberrations (a change in the number of chro-
mosomes from the normal number of 46 for human lym-
phocytes) are not determined by this study plan. 
Conclusion
From the results of this study, it is concluded that the 
hydro-alcoholic extract of Picrorhiza kurroa rhizome does 
not induce chromosome aberration up to 2500 µg/mL 
in final culture concentration both in presence (1% v/v) 
and absence of metabolic activation. Therefore, Picrorhiza 
kurroa rhizome extract can be used as a safe Ayurvedic 
medicine since it manifest its healing effects without caus-
ing genotoxicity. Nevertheless, more scientific data on in 
vivo activities in human is required to clarify the use of 
Picrorhiza kurroa as a therapeutic medicine.
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